Search
Bedaquiline
go.drugbank.com/drugs/DB08903ApprovedInvestigationalBedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial acti...
Synonyms: 1-(6-Bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-olCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigationalTrametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersAfatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalFor oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLevomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigationalLevomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. Levomilnacipran is the more active 1S,2R-enantiomer in the ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesBefunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesEliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigationalEliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease. Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glu...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTedizolid phosphate
go.drugbank.com/drugs/DB09042ApprovedDrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member o...
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalIn contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body … While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects.
Categories: Serotonin Receptor Agonists, Serotonin 5-HT1 Receptor AgonistsSynonyms: (−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinolPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalPalbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmac...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates